Best Picks for Renal Week
Best Picks for Renal Week
Hello, this is Jeffrey Berns from the University of Pennsylvania School of Medicine in Philadelphia. I'm Editor-in-Chief of Medscape Nephrology. Like many nephrologists from around the world, I'll be heading to Denver [Colorado] next week to attend the American Society of Nephrology annual meeting. The weather forecast for Denver next week is quite cold, with occasional snow flurries. It should be an interesting trip to Denver, but I'm looking forward to the meeting very much.
I'm actually participating in one of the early courses on Monday and Tuesday on chronic dialysis. There is a variety of other programs on topics, such as renal pathology, interventional nephrology, geriatric nephrology, and professional development. I just wanted to highlight some of the sessions that I'll probably be attending and have encouraged fellows of my program to attend, and I think will be of interest, primarily to clinical nephrologists.
I always enjoy the plenary sessions, the State-of-the-Art Lectures, the Young Investigator Lecture, and those types of early-morning sessions -- if one is able to get up early in the morning to attend them. On Thursday, there will be a very interesting couple of debates: one on nutritional vs active vitamin D and another on iron supplementation vs erythropoiesis-stimulating agent (ESA) supplementation as well as the appropriate balance of those 2 therapies.
There is also what should be a very interesting session on glomerular disease, talking about MYH9, M-type phospholipase A2, as it relates to membranous nephropathy, and then apolipoprotein L1 as it relates to focal segmental glomerulosclerosis. There will be what should be an interesting session on acute kidney injury; what to give and what to take away, for instance, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) (should those be withdrawn?); use of sodium bicarbonate and acetylcysteine for contrast; and so forth.
On Friday, there's a session that should be interesting on the pathophysiology and treatment of membranous nephropathy and a session on vascular access, which I think should be interesting as well. Then I'll be attending the KDIGO [Kidney Disease: Improving Global Outcomes] report, which is going to talk about updated guidelines and other information related to acute kidney injury, blood pressure, chronic kidney disease (CKD), cardiovascular disease in CKD, drug prescribing in CKD, and CKD prognosis. That's all on Friday.
On Saturday, I'm sure that many people will be at the late-breaking clinical trial sessions, which will be talking about -- among other things -- the report of the frequent hemodialysis network, examining daily in-center and nocturnal home hemodialysis. Other reports that are going to be unveiled then include a clinical trial on focal segmental glomerulosclerosis, several studies relating to hematide, and then the long-awaited SHARP [Study of Heart and Renal Protection] of treatment of dyslipidemia in people with CKD.
There is a session on lupus nephritis; another one that should be interesting on monitoring the generally healthy renal transplant patient; and another on controversies in kidney organ allocation, focusing on -- among other things -- paying potential donors for kidney transplantation.
There will be a session on when and who to dialyse, which should be interesting, and then another KDIGO session reporting evidence-based guidelines for the treatment of glomerulonephritis, including IgA [immunoglobulinA] nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease.
There's another session during the meeting during which Barry Straube, the soon-to-be-retiring Head of Centers for Medicare & Medicaid Services (CMS), will be talking about quality indicators in the era of bundling, which should be interesting.
I always enjoy the meeting, although I find it tiring. I hope that you enjoy it as well. Safe travels to and from Denver from wherever you happen to be living. I look forward to seeing many of my friends and colleagues in Denver during the meeting.
This is Jeffrey Berns from the University of Pennsylvania School of Medicine, Editor-in-Chief of Medscape Nephrology.
Hello, this is Jeffrey Berns from the University of Pennsylvania School of Medicine in Philadelphia. I'm Editor-in-Chief of Medscape Nephrology. Like many nephrologists from around the world, I'll be heading to Denver [Colorado] next week to attend the American Society of Nephrology annual meeting. The weather forecast for Denver next week is quite cold, with occasional snow flurries. It should be an interesting trip to Denver, but I'm looking forward to the meeting very much.
I'm actually participating in one of the early courses on Monday and Tuesday on chronic dialysis. There is a variety of other programs on topics, such as renal pathology, interventional nephrology, geriatric nephrology, and professional development. I just wanted to highlight some of the sessions that I'll probably be attending and have encouraged fellows of my program to attend, and I think will be of interest, primarily to clinical nephrologists.
I always enjoy the plenary sessions, the State-of-the-Art Lectures, the Young Investigator Lecture, and those types of early-morning sessions -- if one is able to get up early in the morning to attend them. On Thursday, there will be a very interesting couple of debates: one on nutritional vs active vitamin D and another on iron supplementation vs erythropoiesis-stimulating agent (ESA) supplementation as well as the appropriate balance of those 2 therapies.
There is also what should be a very interesting session on glomerular disease, talking about MYH9, M-type phospholipase A2, as it relates to membranous nephropathy, and then apolipoprotein L1 as it relates to focal segmental glomerulosclerosis. There will be what should be an interesting session on acute kidney injury; what to give and what to take away, for instance, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) (should those be withdrawn?); use of sodium bicarbonate and acetylcysteine for contrast; and so forth.
On Friday, there's a session that should be interesting on the pathophysiology and treatment of membranous nephropathy and a session on vascular access, which I think should be interesting as well. Then I'll be attending the KDIGO [Kidney Disease: Improving Global Outcomes] report, which is going to talk about updated guidelines and other information related to acute kidney injury, blood pressure, chronic kidney disease (CKD), cardiovascular disease in CKD, drug prescribing in CKD, and CKD prognosis. That's all on Friday.
On Saturday, I'm sure that many people will be at the late-breaking clinical trial sessions, which will be talking about -- among other things -- the report of the frequent hemodialysis network, examining daily in-center and nocturnal home hemodialysis. Other reports that are going to be unveiled then include a clinical trial on focal segmental glomerulosclerosis, several studies relating to hematide, and then the long-awaited SHARP [Study of Heart and Renal Protection] of treatment of dyslipidemia in people with CKD.
There is a session on lupus nephritis; another one that should be interesting on monitoring the generally healthy renal transplant patient; and another on controversies in kidney organ allocation, focusing on -- among other things -- paying potential donors for kidney transplantation.
There will be a session on when and who to dialyse, which should be interesting, and then another KDIGO session reporting evidence-based guidelines for the treatment of glomerulonephritis, including IgA [immunoglobulinA] nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease.
There's another session during the meeting during which Barry Straube, the soon-to-be-retiring Head of Centers for Medicare & Medicaid Services (CMS), will be talking about quality indicators in the era of bundling, which should be interesting.
I always enjoy the meeting, although I find it tiring. I hope that you enjoy it as well. Safe travels to and from Denver from wherever you happen to be living. I look forward to seeing many of my friends and colleagues in Denver during the meeting.
This is Jeffrey Berns from the University of Pennsylvania School of Medicine, Editor-in-Chief of Medscape Nephrology.
Source...